BACLOFEN

Product NDC
72888-010
11-digit product format
728880010
Labeler code
72888
Product ID
72888-010_490e18d8-694e-da7b-e063-6294a90ab450
Type
HUMAN PRESCRIPTION DRUG
Nonproprietary name
BACLOFEN
Dosage form
TABLET
Route
ORAL
Labeler
Advagen Pharma Limited
Application
ANDA209102
Marketing category
ANDA
Marketing start
2018-04-01
Substance
BACLOFEN
Active strength
10 mg/1
Pharmacologic classes
GABA A Agonists [MoA], GABA B Agonists [MoA], gamma-Aminobutyric Acid-ergic Agonist [EPC]
NDC exclude flag
No
Listing certified through
2027-12-31
Current FDA listing
Yes

Orange Book products#

Application-product, Trade name, Ingredient table
Application-productTrade nameIngredientStrengthDosage form / routeTE codesRLD / RSApproval date
A209102-001BACLOFENBACLOFEN5MGTABLET / ORALAB2017-11-28
A209102-002BACLOFENBACLOFEN10MGTABLET / ORALAB2017-11-28
A209102-003BACLOFENBACLOFEN20MGTABLET / ORALAB2017-11-28
A209102-004BACLOFENBACLOFEN15MGTABLET / ORALAB2024-02-05

Therapeutic equivalence codes#

Application-product, TE code table
Application-productTE code
A209102-001AB
A209102-002AB
A209102-003AB
A209102-004AB

openFDA label cross-check#

Cross-check layer: openFDA label JSON enriches search and identifies hydration gaps. The DailyMed Structured Product Label remains the canonical label presentation on FDA.report.

Brand, Generic, Manufacturer table
BrandGenericManufacturerSPL set IDEffective dateAvailable safety fieldsJoin
BACLOFENBACLOFENAdvagen Pharma Limited04dac0f6-cc6c-4959-9bca-a6e4a99690f32026-01-23Warnings, Adverse reactionsExact identifier

Warnings cross-check#

openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.

warnings

WARNINGS a. Neonatal Withdrawal Symptoms: Withdrawal symptoms have been reported starting hours to days after delivery in neonates whose mothers were treated with oral baclofen throughout pregnancy. The symptoms of withdrawal in these infants have included increased muscle tone, tremor, jitteriness, and seizure. If the potential benefit justifies the potential risk to the fetus and oral baclofen is continued during pregnancy, gradua ly reduce the dose and discontinue baclofen before delivery. If slow withdrawal is not feasible, advise the parents or caregivers of the potential for neonatal withdrawal. b. Abrupt Drug Withdrawal: Hallucinations and seizures have occurred on abrupt withdrawal of baclofen. Therefore, except for serious adverse reactions, the dose should be reduced slowly when the drug is discontinued. c. Impaired Renal Function: Because baclofen is primarily excreted unchanged through the kidneys, it should be given with caution, and it may be necessary to reduce the dosage. d. Stroke: Baclofen has not significantly benefited patients with stroke. These patients have also shown poor tolerability to the drug. e. Pregnancy: Baclofen has been shown to increase the incidence of omphaloceles (ventral hernias) in fetuses of rats given approximately 13 times the maximum dose recommended for human use, at a dose which caused significant reductions in food intake and weight gain in dams. This abnormality was not seen in mice or rabbits. There was also an increased incidence of incomplete sternebral ossification in fetuses of rats given approximately 13 times the maximum recommended human dose, and an increased incidence of unossified phalangeal nuclei of forelimbs and hindlimbs in fetuses of rabbits given approximately 7 times the maximum recommended human dose. In mice, no teratogenic effects were observed, although reductions in mean fetal weight with consequent delays in skeletal ossification were present when dams were given 17 and 34 times the human daily dose. There are no studies in pregnant women. Baclofen should be used during pregnancy only if the benefit clearly justifies the potential risk to the fetus.

Adverse reactions cross-check#

openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.

adverse reactions

ADVERSE REACTIONS The most common is transient drowsiness (10 to 63%). In one controlled study of 175 patients, transient drowsiness was observed in 63% of those receiving baclofen compared to 36% of those in the placebo group. Other common adverse reactions are dizziness (5 to 15%), weakness (5 to 15%) and fatigue (2 to 4%). Others reported: Neuropsychiatric: Confusion (1 to 11%), headache (4 to 8%), insomnia (2 to 7%); and, rarely, euphoria, excitement, depression, hallucinations, paresthesia, muscle pain, tinnitus, slurred speech, coordination disorder, tremor, rigidity, dystonia, ataxia, blurred vision, nystagmus, strabismus, miosis, mydriasis, diplopia, dysarthria, epileptic seizure. Cardiovascular: Hypotension (0 to 9%). Rare instances of dyspnea, palpitation, chest pain, syncope. Gastrointestinal: Nausea (4 to 12%), constipation (2 to 6%); and rarely, dry mouth, anorexia, taste disorder, abdominal pain, vomiting, diarrhea, and positive test for occult blood in stool. Genitourinary: Urinary frequency (2 to 6%); and rarely, enuresis, urinary retention, dysuria, impotence, inability to ejaculate, nocturia, hematuria. Other: Instances of rash, pruritus, ankle edema, excessive perspiration, weight gain, nasal congestion. Some of the CNS and genitourinary symptoms may be related to the underlying disease rather than to drug therapy. The following laboratory tests have been found to be abnormal in a few patients receiving baclofen: increased SGOT, elevated alkaline phosphatase, and elevation of blood sugar.

Additional Listing Data#

Finished product
Yes
Brand name base
BACLOFEN
Listing expiration
2027-12-31

Active Ingredients#

Ingredient, Strength table
IngredientStrength
BACLOFEN10 mg/1

Harmonized Identifiers#

Field, Values table
FieldValues
UniiH789N3FKE8
Rxcui197391, 197392, 430902, 2679605

DailyMed Product Concepts#

Product concept, Relation, Version table
Product conceptRelationVersionEffective
1e25d01b-2e92-4765-bec7-8a0fd7bdc346Product name220251208
1b1393e5-f2d8-42f5-a070-e3416d619667Product name120250804
88583480-702d-4dfe-a31c-9c00abd818f8Product name720250729
1cf3c538-592e-4b4b-869e-51d4bf3ca83dProduct name220240703
6e532d1f-e0b5-46eb-a2be-d70bd338df9dProduct name120220613
ef6bc0bf-8134-f06b-70d9-4980df6f808eProduct name520210615
eeec0918-7a2f-44bf-83d6-1216e507adbfProduct name320191217
a5300adb-f538-4abb-a49e-f8f0b8d9ac75Product name120190611

DailyMed Package Descriptions#

Package NDC, Product, Description table
Package NDCProductDescriptionFormQuantityStrengthSPL version
72888-010-00BACLOFEN1000 in 1 BOTTLETABLET10007
72888-010-01BACLOFEN100 in 1 BOTTLETABLET1007
72888-010-05BACLOFEN500 in 1 BOTTLETABLET5007

DailyMed Billing Units#

Package NDC, Billing unit, Product NDC table
Package NDCBilling unitProduct NDCDailyMed indexing SPLSPL versionEffective
72888-010-00EA - Each72888-0102e548b0f-0135-4a1a-a2aa-3391eca8b3b412021-09-07
72888-010-01EA - Each72888-010764ee2b7-852a-4199-839e-509cd7d4480812021-06-02
72888-010-05EA - Each72888-010923df50c-6e77-4e8f-90db-80a06492f41f12021-07-15

DailyMed Dashboard NDC Coverage#

NDC, Dashboard title, SPL version table
NDCDashboard titleSPL versionValidationDashboard ZIP
72888-010BACLOFEN TABLET [ADVAGEN PHARMA LIMITED]5Current NDC, Legacy NDC, 3 package rows20230706_04dac0f6-cc6c-4959-9bca-a6e4a99690f3.zip

DailyMed RxNorm Mappings#

RxCUI, RxNorm string, TTY table
RxCUIRxNorm stringTTYDailyMedSPL version
197391baclofen 10 MG Oral TabletPSN16266972-843e-4ea5-be1f-fb1b1588a5dc8
197391baclofen 10 MG Oral TabletSCD16266972-843e-4ea5-be1f-fb1b1588a5dc8
197391baclofen 10 MG Oral TabletPSN04dac0f6-cc6c-4959-9bca-a6e4a99690f37
2679605baclofen 15 MG Oral TabletPSN04dac0f6-cc6c-4959-9bca-a6e4a99690f37
197392baclofen 20 MG Oral TabletPSN04dac0f6-cc6c-4959-9bca-a6e4a99690f37
430902baclofen 5 MG Oral TabletPSN04dac0f6-cc6c-4959-9bca-a6e4a99690f37
197391baclofen 10 MG Oral TabletSCD04dac0f6-cc6c-4959-9bca-a6e4a99690f37
2679605baclofen 15 MG Oral TabletSCD04dac0f6-cc6c-4959-9bca-a6e4a99690f37
197392baclofen 20 MG Oral TabletSCD04dac0f6-cc6c-4959-9bca-a6e4a99690f37
430902baclofen 5 MG Oral TabletSCD04dac0f6-cc6c-4959-9bca-a6e4a99690f37
2679605baclofen 15 MG Oral TabletSY04dac0f6-cc6c-4959-9bca-a6e4a99690f37
197391baclofen 10 MG Oral TabletPSNee59a379-17d5-487f-b72f-a53e74744a704
197391baclofen 10 MG Oral TabletSCDee59a379-17d5-487f-b72f-a53e74744a704
197391baclofen 10 MG Oral TabletPSNeb690a49-b87b-433f-9afe-2966406fe00e2
197391baclofen 10 MG Oral TabletSCDeb690a49-b87b-433f-9afe-2966406fe00e2
197391baclofen 10 MG Oral TabletPSN2927228a-7a3e-4e1d-ab5f-4407b00f68991
197391baclofen 10 MG Oral TabletPSNaf0ade6c-9dd4-42d3-879e-4201fbe585ee1
197392baclofen 20 MG Oral TabletPSN2927228a-7a3e-4e1d-ab5f-4407b00f68991
197391baclofen 10 MG Oral TabletSCD2927228a-7a3e-4e1d-ab5f-4407b00f68991
197391baclofen 10 MG Oral TabletSCDaf0ade6c-9dd4-42d3-879e-4201fbe585ee1
197392baclofen 20 MG Oral TabletSCD2927228a-7a3e-4e1d-ab5f-4407b00f68991

Packages#

Package NDC, 11-digit format, Description table
Package NDC11-digit formatDescriptionUnitsMarketing startMarketing endSampleExclude flagStatus
72888-010-00728880010001000 TABLET in 1 BOTTLE (72888-010-00) 1000 tablet2018-04-010000-00-00NoNoCurrent
72888-010-0172888001001100 TABLET in 1 BOTTLE (72888-010-01) 100 tablet2018-04-010000-00-00NoNoCurrent
72888-010-0572888001005500 TABLET in 1 BOTTLE (72888-010-05) 500 tablet2018-04-010000-00-00NoNoCurrent